AI Terminal
Pentixapharm Holding AG
Board/Management Information • Mar 3, 2025
8205_rns_2025-03-03_53c7951a-994a-4fb0-88ca-3803e22bac99.html
Board/Management Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 3 March 2025 14:38
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
Pentixapharm Holding AG / Key word(s): Personnel
Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
03.03.2025 / 14:38 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, Germany, March 3, 2025 – Several previously announced personnel changes in the governing bodies of the Pentixapharm Group have taken effect as of March 1, 2025. The Management Board of the parent company Pentixapharm Holding AG is now identical in composition to the Management Board of the wholly owned operational subsidiary Pentixapharm AG. Both companies are now led by Dr. Dirk Pleimes and Henner Kollenberg.
Dr. Andreas Eckert, who was temporarily appointed as sole member of the Management Board of the holding company in November 2024 under § 105(2) of the German Stock Corporation Act following the health-related departure of Pentixapharm founder Dr. Hakim Bouterfa, has returned to the Supervisory Board of Pentixapharm Holding AG. He was re-elected as Chairman there. With his return to the Supervisory Board, Dr. Harald Hasselmann’s Supervisory Board mandate in Pentixapharm Holding AG has also been reactivated. Hasselmann had suspended his mandate since October due to potential conflicts of interest. Frank Perschmann, who had been acting as Chairman of the Supervisory Board of Pentixapharm Holding AG in recent months, left the board as planned with Eckert’s return.
About Pentixapharm
Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds and early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
For more information, please contact:
Pentixapharm Holding AG
Phillip Eckert, Investor Relations
Tel. +49 30 94893232
03.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | [email protected] |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2094397 |
| End of News | EQS News Service |
2094397 03.03.2025 CET/CEST